Now Available

The same alpha-1 therapy trusted for more than 25 years is now available in a convenient liquid formulation.

Frequently asked questions

Not looking for FAQs? Continue to Prolastin.com
but be sure to check back soon for updates.

Check back soon for updates.

Please see accompanying PROLASTIN-C LIQUID Important Safety Information and full Prescribing Information.

BN/PRL/0418/0014(1)

Order FREE Grifols
AlphaKit test kits

to rule out alpha-1


Prescribe PROLASTIN-C LIQUID
(alpha1-proteinase inhibitor [human])

to raise alpha-1 levels with a
15-minute average infusion time1,4 * 


Enroll your patients in the 
PROLASTIN DIRECT program

which offers fully integrated disease management5,6


*PROLASTIN-C LIQUID therapy raises alpha1-antitrypsin levels and antineutrophil elastase activity in the lungs. Although the maintenance of blood serum levels of alpha1-proteinase inhibitor above 11 μM has been historically postulated to provide therapeutically relevant antineutrophil elastase protection, this has not been proven.1

When given at the recommended rate of 0.08 mL/kg/min.3


PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use


  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trial
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.


References

  1. Data on file, Grifols.
  2. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
  3. PROLASTIN®-C LIQUID (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols.
  4. Data on file, PROLASTIN DIRECT program. Grifols.
  5. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.